HTG Molecular Diagnostics, Inc. (HTGM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HTG Molecular Diagnostics, Inc. (HTGM) trades at $0.48 with AI Score 46/100 (Grade C). HTG Molecular Diagnostics, Inc. is a precision medicine company focused on providing molecular profiling solutions. Market cap: $1.06M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for HTGM: HTGM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HTGM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HTGM: the 1 perspectives are evenly split.
How is this calculated? →HTG Molecular Diagnostics, Inc. (HTGM) Healthcare & Pipeline Overview
HTG Molecular Diagnostics, Inc. offers molecular profiling solutions for precision medicine, including instruments, consumables, and software. Their HTG EdgeSeq technology serves biopharmaceutical companies and research institutions by automating sample processing and profiling molecular targets. The company distributes its products in the United States, Europe, and internationally.
What Is the Investment Thesis for HTGM?
HTG Molecular Diagnostics, Inc. operates in the growing precision medicine market, offering potential for revenue expansion through its HTG EdgeSeq technology. Key value drivers include increasing adoption of molecular profiling in oncology and drug development. Growth catalysts include expansion of the product portfolio with new assays and panels. However, the company's negative profit margin of -339.2% and small market capitalization of $1.06M present significant financial risks. Investors should closely monitor HTG's ability to achieve profitability and secure additional funding to sustain operations. The company's beta of 0.99 indicates market correlation.
Based on FMP financials and quantitative analysis
HTGM Key Highlights
- HTG Molecular Diagnostics operates in the precision medicine sector, which is experiencing growth due to advancements in genomics and personalized healthcare.
- The company's HTG EdgeSeq technology offers a differentiated approach to molecular profiling, potentially capturing market share from traditional methods.
- HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, providing a diversified customer base.
- The company's gross margin of 28.2% indicates potential for profitability improvements through economies of scale and product mix optimization.
- HTG's distribution network covers the United States, Europe, and international markets, providing a global reach for its products.
Who Are HTGM's Competitors?
HTGM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HTGM's Key Strengths?
- Proprietary HTG EdgeSeq technology platform.
- Established relationships with key customers in the biopharmaceutical and academic sectors.
- Growing portfolio of molecular profiling assays and panels.
- Distribution network covering key global markets.
What Are HTGM's Weaknesses?
- Negative profit margin and reliance on external funding.
- Small market capitalization and limited financial resources.
- Intense competition in the molecular diagnostics market.
- Dependence on a limited number of key products and customers.
What Could Drive HTGM Stock Higher?
- Potential FDA approval of new HTG EdgeSeq assays, expanding clinical utility.
- Expansion of strategic partnerships with biopharmaceutical companies for companion diagnostics development.
- Increasing adoption of HTG EdgeSeq technology in academic research centers and molecular testing laboratories.
- Publication of clinical studies demonstrating the value of HTG EdgeSeq assays in personalized medicine.
What Are the Key Risks for HTGM?
- Financial-distress signal — its Altman Z-Score of -35.26 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to achieve profitability and reliance on external funding.
- Intense competition in the molecular diagnostics market.
- Technological obsolescence and the emergence of competing technologies.
- Regulatory changes and reimbursement pressures.
- Economic downturns and reduced healthcare spending.
What Are the Growth Opportunities for HTGM?
- Expansion of HTG EdgeSeq Menu: HTG can expand its portfolio of HTG EdgeSeq assays and panels to address new therapeutic areas and disease indications. This includes developing assays for liquid biopsy, infectious diseases, and other emerging areas of interest. The market for liquid biopsy alone is projected to reach billions of dollars in the coming years, presenting a significant opportunity for HTG to capture market share. Timeline: Ongoing.
- Strategic Partnerships with Biopharmaceutical Companies: HTG can forge strategic partnerships with biopharmaceutical companies to co-develop and commercialize companion diagnostics. These partnerships can provide HTG with access to new markets, funding, and expertise. The market for companion diagnostics is growing rapidly, driven by the increasing demand for personalized medicine. Timeline: Ongoing.
- Geographic Expansion into Emerging Markets: HTG can expand its geographic presence into emerging markets, such as Asia-Pacific and Latin America, where the demand for molecular diagnostics is growing rapidly. This expansion can be achieved through strategic partnerships with local distributors and collaborators. The market for molecular diagnostics in emerging markets is expected to grow at a faster pace than in developed markets. Timeline: 2027-2029.
- Development of Integrated Diagnostic Solutions: HTG can develop integrated diagnostic solutions that combine its HTG EdgeSeq technology with other diagnostic modalities, such as imaging and clinical data. This integration can provide clinicians with a more comprehensive view of the patient's condition, leading to more informed treatment decisions. The market for integrated diagnostic solutions is growing, driven by the increasing demand for personalized medicine. Timeline: 2028-2030.
- Leveraging AI and Machine Learning: HTG can leverage artificial intelligence (AI) and machine learning (ML) to enhance its HTG EdgeSeq technology and develop new diagnostic applications. AI and ML can be used to analyze large datasets of molecular profiling data, identify biomarkers, and predict patient outcomes. The market for AI-powered diagnostics is growing rapidly, driven by the increasing availability of data and the advancements in AI and ML technologies. Timeline: Ongoing.
What Opportunities Does HTGM Have?
- Expansion of HTG EdgeSeq menu to address new therapeutic areas.
- Strategic partnerships with biopharmaceutical companies for companion diagnostics.
- Geographic expansion into emerging markets.
- Development of integrated diagnostic solutions.
What Threats Does HTGM Face?
- Technological obsolescence and the emergence of competing technologies.
- Regulatory changes and reimbursement pressures.
- Economic downturns and reduced healthcare spending.
- Intellectual property infringement and patent challenges.
What Are HTGM's Competitive Advantages?
- Proprietary HTG EdgeSeq technology platform.
- Established relationships with biopharmaceutical companies and academic research centers.
- Growing portfolio of HTG EdgeSeq assays and panels.
- Distribution network covering the United States, Europe, and international markets.
What Does HTGM Do?
HTG Molecular Diagnostics, Inc., founded in 1997 and based in Tucson, Arizona, is a life sciences company dedicated to advancing precision medicine through molecular profiling. Originally incorporated as HTG, Inc., the company rebranded to HTG Molecular Diagnostics, Inc. in March 2011 to better reflect its focus. HTG develops, manufactures, and markets instruments, consumables (assay kits), and software designed to automate sample processing and profile various molecular targets. These products enable researchers and clinicians to gain deeper insights into disease mechanisms and develop more effective therapies. The company's key offerings include the HTG Transcriptome Panel and the HTG EdgeSeq product line, which encompasses a range of molecular profiling panels such as the HTG EdgeSeq precision immuno-oncology panel, miRNA whole-transcriptome assay, DLBCL cell of origin assay, Oncology Biomarker Panel, ALKPlus assay, and Pan B-Cell Lymphoma Panel. These panels are designed to analyze specific sets of genes or RNA molecules, providing valuable information for cancer research, drug development, and diagnostic applications. HTG distributes its products directly in the United States and Europe, and through distributors in other parts of Europe and internationally. The company serves a diverse customer base, including biopharmaceutical companies, academic research centers, and molecular testing laboratories, and has a governing agreement with QIAGEN Manchester Limited.
What Products and Services Does HTGM Offer?
- Develop and market instruments for molecular profiling.
- Offer consumables, including assay kits, for use with their instruments.
- Provide software solutions for automating sample processing and data analysis.
- Offer the HTG Transcriptome Panel for comprehensive gene expression analysis.
- Offer HTG EdgeSeq panels for various applications, including immuno-oncology and lymphoma diagnostics.
- Distribute their products directly in the United States and Europe.
- Distribute their products through distributors in other parts of Europe and internationally.
- Serve biopharmaceutical companies, academic research centers, and molecular testing laboratories.
How Does HTGM Make Money?
- Sale of instruments for molecular profiling.
- Recurring revenue from the sale of consumables (assay kits).
- Software licensing and service agreements.
- Strategic partnerships with biopharmaceutical companies for co-development and commercialization.
What Industry Does HTGM Operate In?
HTG Molecular Diagnostics operates within the medical diagnostics and research industry, a segment driven by advancements in genomics, proteomics, and personalized medicine. The market is characterized by intense competition among established players and emerging companies offering innovative diagnostic solutions. Key trends include the increasing adoption of molecular profiling in oncology, drug development, and personalized healthcare. HTG competes with companies like ACOR, AXDX, CWBR, CYTO, and IMPL, focusing on specific niches within the broader diagnostics market. The industry is expected to continue growing, driven by the increasing demand for more precise and personalized diagnostic tools.
Who Are HTGM's Key Customers?
- Biopharmaceutical companies involved in drug discovery and development.
- Academic research centers conducting basic and translational research.
- Molecular testing laboratories providing diagnostic services to clinicians.
Company Profile
HTG Molecular Diagnostics, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Tucson, US. The company is led by CEO John L. Lubniewski. HTGM has traded publicly since 2015.
HTG Molecular Diagnostics, Inc. (HTGM) Valuation Context
Valued at $1.06M, HTGM is classified as a micro-cap stock. Relative to its peer group, HTGM's quantitative score of 46/100 is below the peer average of 64/100.
F-Score 3/9Financial Health
HTG Molecular Diagnostics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.26 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 12 insider filings for HTG Molecular Diagnostics, Inc. break down as 5 sales and 7 purchases. On net that is roughly 9K shares acquired (about $272K) — insiders putting money in tends to read as conviction.
HTGM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in its growth potential.
- Community sentiment has been increasingly positive, with discussions highlighting the innovative aspects of HTG's diagnostic technology.
- Recent partnerships and collaborations have been well-received, signaling strong market interest and potential for expanded reach.
- The growing demand for personalized medicine aligns well with HTG's offerings, positioning the company favorably in a booming sector.
Bear Case
- Concerns about the competitive landscape have been voiced, with some investors wary of how HTG will differentiate itself from larger players.
- Recent earnings reports have raised questions about scalability and operational efficiency, leading to skepticism among analysts.
- Social sentiment has seen some volatility, with bearish opinions surfacing regarding regulatory challenges that could impact growth timelines.
- Market perception remains cautious, as some view HTG as a speculative investment rather than a stable long-term player.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
HTGM Latest News
No recent news available for HTGM.
HTGM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HTGM.
Price Targets
Wall Street price target analysis for HTGM.
HTGM MoonshotScore
What does this score mean?
The MoonshotScore rates HTGM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John L. Lubniewski
CEO
John L. Lubniewski serves as the CEO of HTG Molecular Diagnostics, Inc. His background includes extensive experience in the life sciences and diagnostics industries. He has held leadership positions in various companies, focusing on commercial strategy, business development, and product development. His expertise spans molecular diagnostics, genomics, and personalized medicine. Lubniewski's experience positions him to lead HTG in its mission to advance precision medicine through molecular profiling.
Track Record: Under John L. Lubniewski's leadership, HTG Molecular Diagnostics, Inc. has focused on expanding its HTG EdgeSeq technology platform and developing new molecular profiling assays. He has overseen the company's efforts to establish strategic partnerships with biopharmaceutical companies and expand its geographic reach. Key milestones include the launch of new HTG EdgeSeq panels and the expansion of the company's distribution network.
Common Questions About HTGM (Healthcare)
What does HTG Molecular Diagnostics, Inc. do?
HTG Molecular Diagnostics, Inc. is a precision medicine company that develops and markets molecular profiling solutions based on its proprietary HTG EdgeSeq technology. The company's products include instruments, consumables (assay kits), and software designed to automate sample processing and profile various molecular targets. These solutions enable researchers and clinicians to gain deeper insights into disease mechanisms and develop more effective therapies. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories.
What are the main risks for HTGM?
The main risks for HTGM include its negative profit margin and reliance on external funding, which could impact its ability to sustain operations and invest in growth initiatives. The company also faces intense competition in the molecular diagnostics market, which could limit its ability to gain market share and maintain pricing power. Technological obsolescence and the emergence of competing technologies pose a threat to HTGM's long-term competitiveness. Regulatory changes and reimbursement pressures could also impact the company's profitability. General economic downturns and reduced healthcare spending could negatively affect demand for HTGM's products.
What are the key factors to evaluate for HTGM?
HTG Molecular Diagnostics, Inc. (HTGM) holds an AI score of 46/100 (low). Not financial advice.
How frequently does HTGM data refresh on this page?
HTGM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HTGM's recent stock price performance?
HTG Molecular Diagnostics, Inc. (HTGM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary HTG EdgeSeq technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HTGM overvalued or undervalued right now?
Valuing HTG Molecular Diagnostics, Inc. (HTGM) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HTGM?
Before investing in HTG Molecular Diagnostics, Inc. (HTGM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HTGM to a portfolio?
Key strength of HTG Molecular Diagnostics, Inc. (HTGM): Proprietary HTG EdgeSeq technology platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for HTGM, limiting the depth of financial and market analysis.
- Information is based on publicly available sources and may not be exhaustive.